170 related articles for article (PubMed ID: 22354705)
41. Pharmacological characterisation of cannabinoid receptors inhibiting interleukin 2 release from human peripheral blood mononuclear cells.
Ihenetu K; Molleman A; Parsons M; Whelan C
Eur J Pharmacol; 2003 Mar; 464(2-3):207-15. PubMed ID: 12620515
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids.
Ihenetu K; Molleman A; Parsons ME; Whelan CJ
Eur J Pharmacol; 2003 Jan; 458(1-2):207-15. PubMed ID: 12498928
[TBL] [Abstract][Full Text] [Related]
43. Effects of cannabinoid agonists on sheep sphincter of oddi in vitro.
Sarac B; Durmus N; Altun A; Turan M; Kaya T; Sencan M; Bagcivan I
Pancreatology; 2011; 11(4):428-33. PubMed ID: 21921665
[TBL] [Abstract][Full Text] [Related]
44. Sustained antinociceptive effect of cannabinoid receptor agonist WIN 55,212-2 over time in rat model of neuropathic spinal cord injury pain.
Hama A; Sagen J
J Rehabil Res Dev; 2009; 46(1):135-43. PubMed ID: 19533526
[TBL] [Abstract][Full Text] [Related]
45. Novel halogenated derivates of JWH-018: Behavioral and binding studies in mice.
Vigolo A; Ossato A; Trapella C; Vincenzi F; Rimondo C; Seri C; Varani K; Serpelloni G; Marti M
Neuropharmacology; 2015 Aug; 95():68-82. PubMed ID: 25769232
[TBL] [Abstract][Full Text] [Related]
46. Pre-emptive antinociceptive effects of a synthetic cannabinoid in a model of neuropathic pain.
Guindon J; Desroches J; Dani M; Beaulieu P
Eur J Pharmacol; 2007 Jul; 568(1-3):173-6. PubMed ID: 17555742
[TBL] [Abstract][Full Text] [Related]
47. Involvement of CB1 and CB2 receptors in the modulation of cholinergic neurotransmission in mouse gastric preparations.
Mulè F; Amato A; Baldassano S; Serio R
Pharmacol Res; 2007 Sep; 56(3):185-92. PubMed ID: 17656103
[TBL] [Abstract][Full Text] [Related]
48. Characterization of cannabinoid modulation of sensory neurotransmission in the rat isolated mesenteric arterial bed.
Duncan M; Kendall DA; Ralevic V
J Pharmacol Exp Ther; 2004 Oct; 311(1):411-9. PubMed ID: 15205450
[TBL] [Abstract][Full Text] [Related]
49. CB1 receptor activation in the basolateral amygdala produces antinociception in animal models of acute and tonic nociception.
Hasanein P; Parviz M; Keshavarz M; Javanmardi K
Clin Exp Pharmacol Physiol; 2007; 34(5-6):439-49. PubMed ID: 17439413
[TBL] [Abstract][Full Text] [Related]
50. Inhibitory effect of the cannabinoid receptor agonist WIN 55,212-2 on pentagastrin-induced gastric acid secretion in the anaesthetized rat.
Coruzzi G; Adami M; Coppelli G; Frati P; Soldani G
Naunyn Schmiedebergs Arch Pharmacol; 1999 Dec; 360(6):715-8. PubMed ID: 10619190
[TBL] [Abstract][Full Text] [Related]
51. Antinociceptive effects of the selective CB2 agonist MT178 in inflammatory and chronic rodent pain models.
Vincenzi F; Targa M; Corciulo C; Tabrizi MA; Merighi S; Gessi S; Saponaro G; Baraldi PG; Borea PA; Varani K
Pain; 2013 Jun; 154(6):864-73. PubMed ID: 23518609
[TBL] [Abstract][Full Text] [Related]
52. Caffeine and cannabinoid receptors modulate impulsive behavior in an animal model of attentional deficit and hyperactivity disorder.
Leffa DT; Ferreira SG; Machado NJ; Souza CM; Rosa FD; de Carvalho C; Kincheski GC; Takahashi RN; Porciúncula LO; Souza DO; Cunha RA; Pandolfo P
Eur J Neurosci; 2019 Jun; 49(12):1673-1683. PubMed ID: 30667546
[TBL] [Abstract][Full Text] [Related]
53. Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors.
Desroches J; Charron S; Bouchard JF; Beaulieu P
Neuropharmacology; 2014 Feb; 77():441-52. PubMed ID: 24148808
[TBL] [Abstract][Full Text] [Related]
54. CB
Zheng T; Zhang R; Zhang T; Zhang MN; Xu B; Song JJ; Li N; Tang HH; Wang P; Wang R; Fang Q
Brain Res; 2018 Feb; 1680():155-164. PubMed ID: 29274880
[TBL] [Abstract][Full Text] [Related]
55. A saturated N-acylethanolamine other than N-palmitoyl ethanolamine with anti-inflammatory properties: a neglected story..
Dalle Carbonare M; Del Giudice E; Stecca A; Colavito D; Fabris M; D'Arrigo A; Bernardini D; Dam M; Leon A
J Neuroendocrinol; 2008 May; 20 Suppl 1():26-34. PubMed ID: 18426496
[TBL] [Abstract][Full Text] [Related]
56. Cannabinoid and nitric oxide signaling interplay in the modulation of hippocampal hyperexcitability: Study on electrophysiological and behavioral models of temporal lobe epilepsy in the rat.
Carletti F; Gambino G; Rizzo V; Ferraro G; Sardo P
Neuroscience; 2015 Sep; 303():149-59. PubMed ID: 26135674
[TBL] [Abstract][Full Text] [Related]
57. Analgesic and antiinflammatory effects of cannabinoid receptor agonists in a rat model of neuropathic pain.
Leichsenring A; Andriske M; Bäcker I; Stichel CC; Lübbert H
Naunyn Schmiedebergs Arch Pharmacol; 2009 Jun; 379(6):627-36. PubMed ID: 19152053
[TBL] [Abstract][Full Text] [Related]
58. Role of cannabinoid receptor agonists in mechanisms of suppression of central pain syndrome.
Kukushkin ML; Igon'kina SI; Churyukanov MV; Churyukanov VV; Bobrov MY; Bezuglov VV; Gretskaya NV
Bull Exp Biol Med; 2006 Jul; 142(1):39-42. PubMed ID: 17369898
[TBL] [Abstract][Full Text] [Related]
59. Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers.
Bingham B; Jones PG; Uveges AJ; Kotnis S; Lu P; Smith VA; Sun SC; Resnick L; Chlenov M; He Y; Strassle BW; Cummons TA; Piesla MJ; Harrison JE; Whiteside GT; Kennedy JD
Br J Pharmacol; 2007 Aug; 151(7):1061-70. PubMed ID: 17549048
[TBL] [Abstract][Full Text] [Related]
60. Blockade of D1/D2 dopamine receptors within the nucleus accumbens attenuated the antinociceptive effect of cannabinoid receptor agonist in the basolateral amygdala.
Haghparast A; Ghalandari-Shamami M; Hassanpour-Ezatti M
Brain Res; 2012 Aug; 1471():23-32. PubMed ID: 22765910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
